Sherry McDowell, APRN
Psychiatric/Mental Health · Springfield, OHNPI 1316119027
Payments from drug & device makers
Across 224 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$553
- AbbVie$493
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$422
- Neurocrine Biosciences, Inc.$406
- Otsuka America Pharmaceutical, Inc.$312
- Axsome Therapeutics, Inc.$259
- plus $940 from 13 others
What the payments were for
- Food & beverage$3,32798%
- Education$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 33 | $553 |
| AbbVie | 65 | $493 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $422 |
| Neurocrine Biosciences, Inc. | 16 | $406 |
| Otsuka America Pharmaceutical, Inc. | 20 | $312 |
| Axsome Therapeutics, Inc. | 12 | $259 |
| Teva Pharmaceuticals USA, Inc. | 15 | $254 |
| Indivior Inc. | 10 | $175 |
| Lundbeck LLC | 7 | $122 |
| Vanda Pharmaceuticals Inc. | 4 | $91 |
| Johnson & Johnson | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 3 | $55 |
| Supernus Pharmaceuticals, Inc. | 2 | $44 |
| Braeburn Inc. | 1 | $30 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| Luye Pharma (USA) Ltd. | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $13 |
How this compares
$3,387 in reported general payments places this provider in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 109 | $311,931 |
| Abilify MaintenaAripiprazole | 99 | $277,629 |
| IngrezzaValbenazine Tosylate | 27 | $216,870 |
| Abilify AsimtufiiAripiprazole | 14 | $78,319 |
| PerserisRisperidone | 24 | $63,038 |
| RexultiBrexpiprazole | 33 | $63,004 |
| AustedoDeutetrabenazine | 16 | $50,394 |
| VraylarCariprazine Hcl | 27 | $41,561 |
| Risperdal ConstaRisperidone Microspheres | 24 | $33,771 |
| LybalviOlanzapine/Samidorphan Malate | 19 | $31,526 |
| TrintellixVortioxetine Hydrobromide | 37 | $20,671 |
| FanaptIloperidone | 11 | $11,908 |
| Aripiprazole | 132 | $10,984 |
| Paliperidone ErPaliperidone | 15 | $5,649 |
| Haloperidol Decanoate | 49 | $2,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii, Rexulti | $312 | $418,952146 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $76 | $345,702133 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $406 | $216,87027 claims |
| Indivior Inc.Perseris | $175 | $63,03824 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $254 | $50,39416 claims |
| AbbVieVraylar | $493 | $41,56127 claims |
| Alkermes, Inc.Lybalvi | $553 | $31,52619 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $17 | $20,67137 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $91 | $11,90811 claims |
| Lilly USA, LLCOlanzapine | $19 | $2,58086 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Springfield
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Terri PopovitzCincinnati$161K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.